NCT03447470 2025-01-29
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
Redx Pharma Ltd
Phase 1 Completed
Redx Pharma Ltd
National Institutes of Health Clinical Center (CC)
Sumitomo Pharma America, Inc.
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Georgetown University
Stanford University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)